Published on: 12/16/16
Bloomsberg held a conference on Park Avenue – Cannabis Trends & Legalization Implications. There was a lot to talk about with regards to the future of the cannabis industry.
Cannabis trends move away from smoking. The patent rush is on. CBD gum patent extended to include THC.
The thought-provoking Bloomsberg conference was abuzz as the insiders discussed trends and implications of state-level victories for cannabis legalization. Seeking alpha covered the event.
Smoking marijuana is not what it is all about anymore, and now that it has become legal for recreational use in California many start-ups are looking at innovative ways to capture the rapidly growing market with edibles and delicacies.
Pet treats are produced, and an array of trendy products is sprouting up all over the show. The sad part is, companies who have been holding the candle burning in the difficult, dark ages of prohibition, with products of integrity, might soon be sued by some newbie who won the race to patent some alternative application.
A selection of our products
Smoking cannabis, a thing of the past
With smoking weed being very passé, and considered carcinogenic by most that are hip, and not hippie, products such as CBD gum is becoming more popular. Problem is why would a company want to patent the delivery method even though they did not invent it? It could only be for one reason it seems: to prevent others from using it.
AXIM® owns the patent for chewing gum as a delivery method for cannabinoids, yet other companies have been making gum for some time.
It is sad to see the long struggle to legalization turning into a rush for patents, as stock dealers argue in the comments of this article on weather “Big Pharma” would buy out the companies holding the patents or not.
Business as usual, no thought of patients.
The reason why it is speculated gum shares will go up is because people would rather be chewing than smoking cannabis. Smoking cannabis releases harmful toxins and creates a pungent smell. Gum chewing is much more discrete. Measuring the blood absorption rate of cannabis when it is smoked is difficult and inconsistent whereas with gum or other edibles precise dosing is possible.
Stock sellers speculate and encourage investors – companies that get in early to develop and market these alternatives will be the winners. The analogy of Nicorette gum, the alternative to cigarettes, has been drawn. In the same way, AXIM Biotechnologies’ gum is the alternative to smoking marijuana.
Winners? Where there are winners there are automatically losers. And the winner is (drum roll etc… for getting in early…) AXIM was granted a patent extension for “chewing gum compositions comprising cannabinoids” which now includes cannabinoids such as tetrahydrocannabinol (THC) and cannabidiol (CBD). The previous patent covered CBD-only CanChew Gum products.
It seems every step of the way leads to another level of discernment for consumers and patients. Patients must discern between those who are in the cannabis industry for a quick buck to be made, and those who have truly invested in changing the world into a better place. CBD gum is a medicine, not a cash cow.
Disclaimer: Views expressed here do not necessarily reflect those of Endoca and its staff. This article is not intended to provide medical advice, diagnosis, treatment or cure. Endoca CBD products have not been approved by the US Food and Drug Administration (FDA).